AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03396081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRADO-IC
Description: 1. Help of administrative employees to schedule the first medical visits after an hospitalization for heart failure.~2. Home nurse's visiting program, during 2 to 6 months after the hospitalization for heart failure.
Study NCT03396081 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No intervervention Usual Care
Description: Advices about the care pathway, provided by care givers. Prescription of home nurse's visits if needed.
Study NCT03477188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatosensorial and Vestibular Exercises
Description: In the experimental group, the subjects who were taken to the somatosensorial and vestibular exercises program after pre- treatment evaluations. The subjects in this group were given classical physiotherapy and somatosensorial combined with vestibular exercise performed 5-7 days a week, 1 set of 10 times with physiotherapist control. In the content of the training, in addition to the general physiotherapy program applied for Brunnstrom and Bobath exercises and spasticity inhibition according to in-bed mobility, Flask and spasticity conditions in the experimental group, a mutual study program was prepared with Cawthorne-Cooksey and Frenkel exercises in the bed, then balance and walking will be performed with the exercises
Study NCT03477188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Group
Description: In the control group, The subjects who were taken into the study were taken to the classical physiotherapy based on Bobath and Brunnstrom will be applied to increase the mobilization and spasticity up to the discharge stage known as 5-7 days a week
Study NCT01914133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals.
Study NCT02713841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin (INH)
Description: recombinant human insulin administered with Adagio-01 inhaler device
Study NCT02713841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sc insulin lispro (LIS)
Description: insulin lispro administered subcutaneously
Study NCT01639521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01639521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01639521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT01639521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: Given IV
Study NCT01639521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT01639521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC
Study NCT01639521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02571231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFV + and - VG
Description: High frequency ventilation with and without volume guarantuee
Study NCT00302666 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Valette (Dienogest/EE30, BAY86-5038)
Description: Oral contraceptive extended cycles
Study NCT00302666 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Valette (Dienogest/EE30, BAY86-5038)
Description: Oral contraceptive conventional cycles
Study NCT02541487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Alli-nutritional supplement
Description: Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
Study NCT01452217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretin
Description: Secretin 1 IU/kg over 3 min
Study NCT04345432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study.
Study NCT04345432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study.
Study NCT01914133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given prior to meal the standardized meal
Study NCT01275638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
Study NCT03034291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White chocolate
Study NCT02782715 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients will be treated on study with a course of SBRT treatment by a radiation oncologist. Three SBRT dose levels targeting the primary tumor will be evaluated; level I: 6 Gy x 5 fractions (a common palliative dose), level II: 8 Gy x 5 fractions, and level III: 10 Gy x 5 fractions (a common definitive dose).
Study NCT02782715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation (MWA)
Description: Performed under sedation using ultrasound and computed tomography (CT) guidance for percutaneous antenna placement and confirmation. Depending on size and location of tumor, one to three antennas (Certus 140; NeuWave Medical) will be used. The system is an FDA-approved, high-powered third-generation MW device that uses CO2 gas cooling to prevent shaft heating. The gas cooling allows the probes to be stuck into tissue by creating a small ice ball at the tip using the Joule-Thomson method, similar to the tissue cooling mechanism of cryoablation systems. Probes are 17-gauge, and various ablation zone configurations are available depending on the probe selected. An ablation protocol using the 65W power setting for 5 minutes will be used for most patients. Ultrasound will be used for real-time monitoring of the extent of ablation to achieve a 5mm margin beyond tumor, and immediate post-procedure imaging performed using contrast-enhanced CT (CECT) for patients with adequate renal functions.
Study NCT02785757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrombin Generation Assay
Study NCT03929042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posture correction girdle
Description: Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
Study NCT01983865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to birch pollen
Study NCT02772380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation following induction of VT/VF
Description: Up to 10 attempts to induce two VF/VT episodes for defibrillation testing
Study NCT01457339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
Study NCT01457339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule(s) for oral use taken once daily for 30 days
Study NCT03831503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-A002
Description: Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).
Study NCT03831503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.
Study NCT03831503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dengue Fever Antibodies (IgG)
Description: To determine if the subject is Dengue seronegative at baseline
Study NCT00950417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Study NCT03694522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Administered by intravenous infusion over approximately 30 minutes
Study NCT03529149 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Urapidil Hydrochloride Injection
Description: Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV>37cm/s of （middle cerebral artery)MCA, PI \< 1.34cm/s, aMFV>40cm/s of (basilar artery)BA, PI \< 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure.
Study NCT03529149 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Urapidil Hydrochloride Injection
Description: Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV>37cm/s of （middle cerebral artery)MCA, PI \< 1.34cm/s, aMFV>40cm/s of (basilar artery)BA, PI \< 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure.
Study NCT03694522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion over approximately 30 minutes
Study NCT03694522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: mFOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours
Study NCT03694522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modified FOLFOX6
Description: mFOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours
Study NCT00753922 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface
Description: Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.
Study NCT02519231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 440mg 1x pid
Study NCT02519231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet 440mg 1x pid
Study NCT00196937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study NCT05176028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: For individuals of control group, hot pack applied for 20 minutes in the sitting position, Interferential Current was applied for the analgesic effect at a constant 100 Hz frequency on the anterior, posterior, superior and inferior part of the operated shoulder. By increasing the current slowly, the dosage of the current was adjusted to such a degree that the patient could tolerate it.
Study NCT02981459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks
Study NCT03054129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation and balance training
Description: Stretching will be applied as hold-relax technique in Proprioceptive Neuromuscular Facilitation for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.~Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program.
Study NCT03054129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: Rehabilitation program will be same in this group except balance exercises.
Study NCT01823588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led reminder through email.
Description: Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.~Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.
Study NCT05249218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase B - Extra 1 Phe exchange from fruits/vegetables containing Phe from 76-100mg/100g
Description: Usual low Phe diet + 60g fruits/vegetables containing Phe from 76-100mg/100g
Study NCT05249218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase C - Extra 2 Phe exchanges from fruits/vegetables containing Phe from 76-100mg/100g
Description: Usual low Phe diet + 120g fruits/vegetables containing Phe from 76-100mg/100g
Study NCT05249218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase D - Extra 1 Phe exchange from milk or yoghurt
Description: Usual low Phe diet but 1 x 50 mg extra Phe exchange from milk or yoghurt
Study NCT05249218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase E - Extra 2 Phe exchanges from milk or yoghurt
Description: Usual low Phe diet but 2 x 50 mg extra Phe exchange from milk or yoghurt eaten daily
Study NCT02739672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)
Description: Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once
Study NCT02739672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TWYNSTA(Telmisartan+Amlodipine besylate)
Description: TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
Study NCT02739672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once
Study NCT01304823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lactisole
Description: flavoring agent/sweet taste antagonist
Study NCT00450749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT00450749 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo radical prostatectomy
Study NCT00450749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo radical prostatectomy
Study NCT00450749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00450749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT05176028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascial release
Description: Fascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the cervical, thoracolumbar and upper extremity areas until tissue loosening and releasing were felt.
Study NCT00450749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lycopene
Description: Given PO
Study NCT01959971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab
Description: Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous
Study NCT01959971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous
Study NCT00588276 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 124I-Iodo-Azomycin Galacto-Pyranoside
Description: You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three \*IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
Study NCT03396458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis B serology
Description: A serum specimen will be taken and assessed for hepatitis B serology (HBsAg, anti-HBs and anti-HBc).
Study NCT03396458 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will be asked to fill in a questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection (e.g. sharing toothbrushes, HBV infected family member) and HBV vaccination status.
Study NCT02594878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronatdinatrium
Study NCT02594878 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Natrium chloride 9mg/ml
Study NCT01177488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation Therapeutic Exposure (BATE)
Description: This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.
Study NCT01177488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapeutic Exposure (BATE)
Description: This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.